ArticleBMC cancer2026

Inhibition of the ATR-CHK1 signaling pathway sensitizes MCPyV-positive Merkel cell carcinoma to gemcitabine.

Evelyn V Proctor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.